In addition, the objective response rate increased from 17% to 27% when PD-L1 monoclonal antibody atezolizumab was applied in combination with vascular endothelial growth factor (VEGF) monoclonal antibody bevacizumab in advanced HCC, compared to the monotherapy of atezolizumab (6). Here, VEGFA is linked to hepatocellular carcinoma.